Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer

I Sekine; H Nokihara; K Takeda; Y Nishiwaki; K Nakagawa; H Isobe; K Mori; K Matsui; N Saijo; T Tamura

doi:10.1038/sj.bjc.6604233

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer

Br J Cancer. 2008 Feb 26;98(4):693-6. doi: 10.1038/sj.bjc.6604233. Epub 2008 Feb 5.

Authors

I Sekine¹, H Nokihara, K Takeda, Y Nishiwaki, K Nakagawa, H Isobe, K Mori, K Matsui, N Saijo, T Tamura

Affiliation

¹ Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. [email protected]

Abstract

Patients with previously untreated extensive-disease small-cell lung cancer were treated with irinotecan 60 mg m(-2) on days 1 and 8 and cisplatin 60 mg m(-2) on day 1 with (n=55) or without (n=54) etoposide 50 mg m(-2) on days 1-3 with granulocyte colony-stimulating factor support repeated every 3 weeks for four cycles. The triplet regimen was too toxic to be considered for further studies.

Publication types

Clinical Trial, Phase II
Comparative Study
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Carcinoma, Small Cell / drug therapy*
Cisplatin / administration & dosage
Etoposide / administration & dosage
Female
Humans
Irinotecan
Lung Neoplasms / drug therapy*
Male
Middle Aged
Prospective Studies
Survival Rate

Substances

Etoposide
Irinotecan
Cisplatin
Camptothecin